Though patient use of cannabinoids for the treatment of IBD has increased, clinical decision making on whether to formally recommend it as treatment remains difficult.
Researchers aimed to better elucidate the role of fDPP-4 levels as a biomarker of IBD activity and to correlate it with certain clinical parameters.
Diet directly impacts the gut microbiome, which directly affects inflammatory responses in the gut.
Researchers assessed the prevalence of symptoms of anxiety and depression in adult patients with irritable bowel disease.
The U-ACCOMPLISH induction study evaluated the efficacy and safety of upadacitinib in 515 adults with moderate to severe ulcerative colitis.
Researchers evaluated gastrointestinal-related adverse events in patients with psoriatic arthritis and ankylosing spondylitis who were initiating secukinumab.
Researchers summarized the current knowledge on treatment options for extraintestinal manifestations in patients with IBD, while calling attention to gaps in the research.
Initiation of opioid use during a flare of symptoms can eventually lead to chronic opioid use (COU), which can have detrimental effects on a patient’s IBD, as well as their overall clinical health.
Researchers conducted a phase 2a study to determine the safety and efficacy of ABX464 in patients with moderate to severe ulcerative colitis.
Researchers investigated whether psychological comorbidities predated the diagnosis and propagation of inflammatory bowel disease.
Investigators compared rates of pouchitis and pouch failure among patients with and without primary sclerosing cholangitis.
The authors review gut dysfunction and microbiota changes during HIV infection and IBD and discuss how they may induce a dysfunctional mucosal barrier, dysbiosis, and changes on the cellular level, including monocytes, macrophages, and dendritic cells.
Researchers analyzed the effectiveness of tofacitinib for the treatment of moderate to severe ulcerative colitis.
Researchers assessed the risk for severe COVID-19 in patients with microscopic colitis vs the general population.
Investigators assessed whether patients with UC had autoantibodies against integrin αvβ6, a highly specific and sensitive diagnostic biomarker.
The pediatric approval was based on data from the multicenter, randomized, double-blind phase 3 ENVISION I study.
The PROTECT-ASUC Study Group conducted a multicenter, observational, case-control study to assess the impact of the COVID-19 pandemic on the management of acute severe ulcerative colitis.
A team of investigators sought to determine how concomitant proton pump inhibitor treatment influences response to infliximab therapy in patients with inflammatory bowel disease.
Investigators performed a literature review of current strategies for monitoring kidney function in patients undergoing treatment with 5-ASA for inflammatory bowel disease.
The submission is supported by data from the True North trial that assessed ozanimod as an induction and maintenance therapy for adults with moderately to severely active UC who had an inadequate response to prior treatment.